Virginia Hernández1, Carlos Llorente2, Enrique de la Peña2, Elia Pérez-Fernández3, Ana Guijarro2, Ignacio Sola2. 1. Urology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain. Electronic address: vhernandez@fhalcorcon.es. 2. Urology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain. 3. Research Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
Abstract
INTRODUCTION: Over the last 2 decades, there has been a major increase in active surveillance (AS) as a therapeutic alternative in urological tumors regarded to be of low risk. Owing to the findings of significant clinical outcomes in our series, this report presents an update of our AS program in patients with recurrent non-muscle-invasive bladder tumor. The objective was to confirm the oncological long-term safety of this protocol and to determine possible variables associated with progression. MATERIALS AND METHODS: Cohort of patients included in AS between 1999 and 2014. INCLUSION CRITERIA: recurrent papillary tumors, previous pTa-pT1, G1-G2, shorter than 1cm, and fewer than 5 tumour sites. EXCLUSION CRITERIA: prior G3, CIS (carcinoma in situ), or positive-result cytology. All patients underwent close monitoring with flexible cystoscopy every 3 to 4 months for the first 2 years. After this time, follow-ups were conducted every 6 months, alternating between cystoscopy and ultrasound. Urinary cytology test was performed at all visits. RESULTS: In all, 252 AS periods in 186 patients were studied, with a median follow-up of 6 years. Out of all periods, 203 (80.6%) underwent active treatment. After remaining under observation, 86.4% had not progressed in stage, and 79.3% in grade. Of these patients, 4 experienced progression to T2; all of them were previously T1G2. CONCLUSIONS: AS in a high-selectivity group of patients with recurrent non-muscle-invasive bladder tumor is feasible and oncologically safe in the long term. Patients with previous history of T1 should not be included in AS protocols even when very small recurrences are diagnosed.
INTRODUCTION: Over the last 2 decades, there has been a major increase in active surveillance (AS) as a therapeutic alternative in urological tumors regarded to be of low risk. Owing to the findings of significant clinical outcomes in our series, this report presents an update of our AS program in patients with recurrent non-muscle-invasive bladder tumor. The objective was to confirm the oncological long-term safety of this protocol and to determine possible variables associated with progression. MATERIALS AND METHODS: Cohort of patients included in AS between 1999 and 2014. INCLUSION CRITERIA: recurrent papillary tumors, previous pTa-pT1, G1-G2, shorter than 1cm, and fewer than 5 tumour sites. EXCLUSION CRITERIA: prior G3, CIS (carcinoma in situ), or positive-result cytology. All patients underwent close monitoring with flexible cystoscopy every 3 to 4 months for the first 2 years. After this time, follow-ups were conducted every 6 months, alternating between cystoscopy and ultrasound. Urinary cytology test was performed at all visits. RESULTS: In all, 252 AS periods in 186 patients were studied, with a median follow-up of 6 years. Out of all periods, 203 (80.6%) underwent active treatment. After remaining under observation, 86.4% had not progressed in stage, and 79.3% in grade. Of these patients, 4 experienced progression to T2; all of them were previously T1G2. CONCLUSIONS: AS in a high-selectivity group of patients with recurrent non-muscle-invasive bladder tumor is feasible and oncologically safe in the long term. Patients with previous history of T1 should not be included in AS protocols even when very small recurrences are diagnosed.
Authors: Roman Sosnowski; Hubert Kamecki; Steven Joniau; Jochen Walz; John Dowling; Mark Behrendt; Zachary Klaassen; Joan Palou; Hendrik van Poppel Journal: Cent European J Urol Date: 2020-07-28
Authors: Ekaterina Olkhov-Mitsel; Andrea J Savio; Ken J Kron; Vaijayanti V Pethe; Thomas Hermanns; Neil E Fleshner; Bas W van Rhijn; Theodorus H van der Kwast; Alexandre R Zlotta; Bharati Bapat Journal: Transl Oncol Date: 2017-02-03 Impact factor: 4.243
Authors: Melissa García-Caballero; José Antonio Torres-Vargas; Ana Dácil Marrero; Beatriz Martínez-Poveda; Miguel Ángel Medina; Ana R Quesada Journal: Pharmaceutics Date: 2022-01-21 Impact factor: 6.321
Authors: Matteo Ferro; Evelina La Civita; Antonietta Liotti; Michele Cennamo; Fabiana Tortora; Carlo Buonerba; Felice Crocetto; Giuseppe Lucarelli; Gian Maria Busetto; Francesco Del Giudice; Ottavio de Cobelli; Giuseppe Carrieri; Angelo Porreca; Amelia Cimmino; Daniela Terracciano Journal: J Pers Med Date: 2021-03-23